PRAX Overview

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is456.71 USD with a low forecast of 95.00 USD and a high forecast of 843.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Praxis Precision Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Praxis Precision Medicines Inc. EPS for the last quarter amounts to -3.49 USD, increased 19.11

Praxis Precision Medicines Inc (PRAX) has 168 emplpoyees as of March 11 2026.

Today PRAX has the market capitalization of 8.63B USD.